Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gw Pharma ADR (NQ: GWPH )

215.03 USD +0.18 (+0.08%)
Streaming Delayed Price Updated: 11:29 AM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Gw Pharma ADR

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference
From GlobeNewswire News Releases
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
From GlobeNewswire News Releases
Should you invest in Alibaba, Charles Schwab, GW Pharmaceuticals, UnitedHealth Group, or Uber?
InvestorsObserver issues critical PriceWatch Alerts for BABA, SCHW, GWPH, UNH, and UBER. 
From PR Newswire
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
From GlobeNewswire News Releases
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
From GlobeNewswire News Releases
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
From GlobeNewswire News Releases
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community
From GlobeNewswire News Releases
Medical Cannabis Legalization Helps Destigmatize Related Products
FinancialBuzz.com News Commentary 
From PR Newswire
Legalization Efforts Continue to Drive the Cannabis Market Growth
FinancialBuzz.com News Commentary 
From PR Newswire
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-o
This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine 
From GlobeNewswire News Releases
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
From GlobeNewswire News Releases
Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
- Nearly one-third of survey respondents indicated use of THC-containing cannabis for Multiple Sclerosis (MS) symptom management 
From GlobeNewswire News Releases
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors
From GlobeNewswire News Releases
Legislative Breakthroughs Propel the Medical Cannabis Industry Forward
FinancialBuzz.com News Commentary 
From PR Newswire
GW Pharmaceuticals to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress
From GlobeNewswire News Releases
Billion Dollar Cannabidiol Infused Products Market Growing Usage Continues to Skyrocket
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Billion Dollar Cannabidiol Infused Products Market Growing Usage Continues to Skyrocket
Financialnewsmedia.com News Commentary 
From PR Newswire
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
From GlobeNewswire News Releases
Land Betterment Corporation Appoints Sustainability and Impact Industry Executive, Cabot Brown to Leadership Council
Tags Responsible Business & Employee Engagement
From 3BL Media: Corporate Social Responsibility, Energy and Health News
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020
From GlobeNewswire News Releases
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
From GlobeNewswire News Releases
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug
From GlobeNewswire News Releases
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
From GlobeNewswire News Releases
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020
From GlobeNewswire News Releases
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020
From GlobeNewswire News Releases
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.